Trial Site Detail
Drug: |
CB-839 + Talazoparib |
|||
|---|---|---|---|---|
Trial: |
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Terminated |
|||
UAB Comprehensive Cancer Center1802 6th Ave. South |
Principal Investigator: |
Erica Stringer-Reasor, MD |
|---|---|
Contact: |
Likesar (Keisha) McCray 205-975-7265 lmccray@uab.edu |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
UAB Comprehensive Cancer Center Website: |
http://www3.ccc.uab.edu/patientresources/clinicaltrials.html |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.